Q4 2024 Holdings
Filed 2025-02-14 | 47 holdings | $704.4M | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Cullinan Therapeutics, Inc.(CGEM) | Common | 230031106 | $93.2M | 7,648,268 | 13.2% |
| Crinetics Pharmaceuticals Inc.(CRNX) | Common | 22663K107 | $31.5M | 617,035 | 4.5% |
| Edgewise Therapeutics Inc(EWTX) | Common | 28036F105 | $28.8M | 1,079,316 | 4.1% |
| Insmed Incorporated(INSM) | Common | 457669307 | $26.9M | 389,611 | 3.8% |
| Natera Inc(NTRA) | Common | 632307104 | $25.4M | 160,626 | 3.6% |
| Mirum Pharmaceuticals Inc(MIRM) | Common | 604749101 | $24.4M | 589,579 | 3.5% |
| Disc Medicine Inc(IRON) | Common | 254604101 | $22.0M | 346,401 | 3.1% |
| Lantheus Holdings Inc(LNTH) | Common | 516544103 | $21.1M | 236,213 | 3.0% |
| Zai Lab Ltd(ZLAB) | Common | 98887Q104 | $21.0M | 800,000 | 3.0% |
| Avidity Biosciences Inc(RNA) | Common | 05370A108 | $20.4M | 702,981 | 2.9% |
| Iovance Biotherapeutics Inc(IOVA) | Common | 462260100 | $19.8M | 2,673,905 | 2.8% |
| PTC Therapeutics Inc(PTCT) | Common | 69366J200 | $19.6M | 434,767 | 2.8% |
| Wave Life Sciences PTE LTD(WVE) | Common | Y95308105 | $18.4M | 1,489,237 | 2.6% |
| Scholar Rock Holding Corp.(SRRK) | Common | 80706P103 | $18.0M | 416,144 | 2.6% |
| Moonlake Immunotherapeutics(MLTX) | Class A Ord | 61559X104 | $17.1M | 315,230 | 2.4% |
| Olema Pharmaceuticals, Inc.(OLMA) | Common | 68062P106 | $17.0M | 2,912,550 | 2.4% |
| Ultragenyx Pharmaceutical Inc(RARE) | Common | 90400D108 | $16.5M | 391,018 | 2.3% |
| Context Therapeutics Inc(CNTX) | Common | 21077P108 | $15.4M | 14,705,882 | 2.2% |
| Guardant Health Inc(GH) | Common | 40131M109 | $13.8M | 452,739 | 2.0% |
| Revolution Medicines, Inc.(RVMD) | Common | 76155X100 | $13.7M | 313,817 | 1.9% |
| iTeos Therapeutics, Inc.(5E7) | Common | 46565G104 | $13.4M | 1,745,943 | 1.9% |
| Cartesian Therapeutics Inc(RNAC) | Common | 816212302 | $12.9M | 721,139 | 1.8% |
| Rocket Pharmaceuticals, Inc.(RCKT) | Common | 77313F106 | $12.8M | 1,020,559 | 1.8% |
| Akero Therapeutics Inc(AKRO) | Common | 00973Y108 | $12.8M | 460,617 | 1.8% |
| Trevi Therapeutics Inc(TRVI) | Common | 89532M101 | $12.8M | 3,094,896 | 1.8% |
| Twist Bioscience Corp(TWST) | Common | 90184D100 | $12.4M | 267,497 | 1.8% |
| Compass Therapeutics, Inc.(CMPX) | Common | 20454B104 | $12.4M | 8,567,896 | 1.8% |
| Janux Therapeutics Inc(JANX) | Common | 47103J105 | $12.3M | 230,000 | 1.7% |
| Replimune Group Inc(REPL) | Common | 76029N106 | $11.5M | 950,000 | 1.6% |
| Nuvation Bio Inc(NUVB) | Common | 67080N101 | $11.1M | 4,164,178 | 1.6% |
| Vera Therapeutics Inc.(VERA) | Class A Ord | 92337R101 | $10.9M | 257,788 | 1.5% |
| Ideaya Biosciences, Inc.(IDYA) | Common | 45166A102 | $10.6M | 414,035 | 1.5% |
| Relay Therapeutics Inc.(RLAY) | Common | 75943R102 | $9.3M | 2,268,825 | 1.3% |
| United Therapeutics Corp.(UTHR) | Common | 91307C102 | $8.1M | 23,000 | 1.2% |
| Arcturus Therapeutics Holdings(ARCT) | Common | 03969T109 | $7.8M | 459,943 | 1.1% |
| Xenon Pharmaceuticals Inc(XENE) | Common | 98420N105 | $7.7M | 197,212 | 1.1% |
| Stoke Therapeutics Inc(STOK) | Common | 86150R107 | $7.6M | 685,826 | 1.1% |
| Aquestive Therapeutics Inc(AQST) | Common | 03843E104 | $5.7M | 1,611,833 | 0.8% |
| Axsome Therapeutics Inc(AXSM) | Common | 05464T104 | $4.2M | 50,000 | 0.6% |
| Sutro Biopharma, Inc. | Common | 869367102 | $4.0M | 2,160,062 | 0.6% |
| Werewolf Therapeutics, Inc.(HOWL) | Common | 95075A107 | $3.5M | 2,388,011 | 0.5% |
| Design Therapeutics Inc(DSGN) | Common | 25056L103 | $3.5M | 559,547 | 0.5% |
| Zentalis Pharmaceuticals, Inc.(ZNTL) | Common | 98943L107 | $3.4M | 1,106,851 | 0.5% |
| Veru Inc.(VERUEUR) | Common | 92536C103 | $2.8M | 4,285,365 | 0.4% |
| Adaptimmune Therapeutics plc(ADAPY) | Sponsored ADR | 00653A107 | $2.7M | 5,095,912 | 0.4% |
| ALX Oncology Holdings Inc.(ALXO) | Common | 00166B105 | $2.3M | 1,391,434 | 0.3% |
| Repare Therapeutics, Inc.(RPTX) | Common | 760273102 | $1.6M | 1,231,154 | 0.2% |